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Summ~-y 
10 patients with borderline and lepromatous leprosy were sdected for a prolonged trial with 
recombinant interferon 3, (rIFN-3,).  Patients received 30/zg intradermally for six injections over 
a 9-d period, and then either 100/zg intradermally every 1 mo for 10 mo or every 2 wk for 
5 mo (total, 1.2 mg). Erythema nodosum leprosum (ENL) was induced in 60% of the patients 
within 6-7 mo, as compared with an incidence of 15%  per year with multiple drug therapy 
alone. The mean whole-body reduction in bacterial index over the first 6 mo was 0.9 log units. 
Cutaneous induration at the intradermal injection sites of >--15 mm predicted the development 
of a subsequent reactional state. Monocytes obtained from patients receiving the lymphokine 
demonstrated an increased respiratory burst and a 2.5-5.1-fold increase in tumor necrosis factor 
ot (TNF-cr  secretion in response to agonists. Patients in ENL had an even higher release of TNF-o~ 
from monocytes as wen as high levels of TNF-c~ in the plasma (mean, 2,000 pg/ml). Thalidomide 
therapy was required to treat the systemic manifestations of ENL. Control of toxic symptoms 
with thalidomide  was associated with a 50-80% reduction in agonist-stimulated monocyte TNF-ol 
secretion. IFN-3, enhanced the monocyte release of TNF-ot by 3-7.5-fold (agonist dependent) 
when added to patient's cells in vitro, and this could be suppressed by the in vitro addition of 
10/~g/ml of thalidomide. 
O 
ur previous studies have described the response of pa- 
tients with lepromatous leprosy to the administration 
of rIFN~ (1-3). This T cell- and NK ceU -derived lymphokine 
is a major activator of monocyte/macrophage antimicrobial 
activity, and activation is attributed to the enhancement of 
oxygen radical  formation (4).  The anergy of lepromatous 
leprosy patients to antigens ofMFobacterium  leprae is reflected 
in their inability to produce IFN-3, (5). We therefore consid- 
ered that replacement therapy with rIFN-~/might be useful 
in these patients. Our studies, initiated in 1985 with the in- 
tradermal injection of rIFN-3, to multibacillary patients, re- 
vealed the local accumulation of T cells and monocytes, the 
destruction of parasitized  macrophages, and a reduction in 
the number of add-fast bacilli (AFB) 1 at the site of injec- 
tion (1-3).  More recently,  10 daily intramuscular injections 
1 Abbreviations used in this paper: AFB, acid-fast bacilli; BCG,  Bacillus 
Calmette-Guerin; RI., bacterial index; BL, borderline lepromatous leprosy; 
CWP-ML,  cell wall protein  of M.  leprae; ENL,  erythema  nodosum 
leprosum; LL, lepromatous leprosy; LAM-ML, lipoarabinomannan of 
M. l~rae; ML, Mycobacterium /eprae; MDT, multidrug  therapy; PGL-I, 
phenolic glycolipid I; PPD, purified protein derivative of tuberculin. 
of 10-30/zg rIFN-'y/m  z led to a systemic, cutaneous T cell 
infiltrate, although a reduction in AFB was not observed (6). 
We now report our experience with the administration 
ofrIFN-'y to lepromatous leprosy for 6-10 mo. Lymphokine 
injections were associated with the development of erythema 
nodosum leprosum (ENL) in 6 of 10 patients. In addition, 
an enhanced reduction of whole body bacterial load was noted. 
Monocytes obtained from ENL patients secreted high levds 
of TNF-ol. Thalidomide therapy of systemic ENL promptly 
led to a cessation of symptoms associated with a reduction 
in TNF-ot production. The effects of IFN-3, and thalidomide 
on TNF-oe production could be reproduced in vitro. 
Materials and Methods 
Patient Population.  10 lepromatous leprosy patients diagnosed 
according to the R.idley-Jopling  classification  (7) (three borderline 
lepromatous [BL], two subpolar lepromatous ILLs], and five  polar 
lepromatous [LL]) from the Leprosy Out-Patient Unit, Oswaldo 
Cruz Foundation (Rio de Janeiro, Brazil) were selected  for the in 
vivo rlFN-~/injections (Table 1). All patients had been treated for 
3-8 mo (mean, 3.9 mo) with multidrug therapy (MUr) (600 mg 
Rifampin and 300 mg clofazimine, monthly supervised, and 100 
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The mean •  SEM bacterial index (RI.) at diagnosis  for all 10 pa- 
tients was 3.0 _+ 0.25, and at initiation of the study 2.49 •  0.36. 
Medication was continued during the study. B.I.s reported here 
for each subject were determined from slit smears collected from 
six sites on the body. None of the patients had presented with any 
reactional manifestations before the beginning of the study. For 
in vitro TNF-~ measurements, blood cells from nine normal donors 
(laboratory personnel), 15 lepromatous leprosy patients (seven BL, 
five LLS, and three LL),  and 13 lepromatous patients (four BL, 
three LLS, and six LL) with ENL were tested. These patients had 
been treated for 0-2 yr with Mur. Seven ENL patient blood samples 
were taken before starting treatment with thalidomide. The other 
six patients had been treated with thalidomide (300 rag/d) for 1-2 
wk before blood samples were collected. 
89 LL/BL patients diagnosed and treated with ~  at the same 
clinic from 1 yr before and during the study were evaluated  for 
their rate of reduction in B.I. during 18 mo of therapy.  The pa- 
tients  were  selected  for compliance  and  for clinical  matching 
(LL/BL) with the study population and were used as controls. The 
mean •  SEM B.I. at diagnosis for all 89 patients was 2.92 •  0.06, 
and at 3 mo after initiation of therapy (about the mean time the 
test group entered into the study) was  2.35  +  0.13. 
rlFN-T Injections.  rlFN-3' (6507; Boehringer Ingelheim, Ingel- 
heim am P,.hein, Germany) was purified from Escherichia coli trans- 
fected with cDNA from human rIFN-% The lyophilized product 
was reconstituted in pyrogen-free sterile distilled water as described 
(1) and had asp act of 2  x  107 U/mg of protein. After written 
consent, lepromatous patients were injected into a leprosy lesion 
with six intradermal 100-/~1 injections of 30/~g rIFNw (three daily 
injections, 3 d rest, and another three daily injections). 1 mo after 
the last 30-/zg injection, patients received the next intradermal in- 
jection (100/zl) of 100/~g rlFN-3~ in the back. A total of 10 100-/~g 
doses were administered: six patients were injected on a monthly 
basis and four patients were injected every 2 wk. Patients were evalu- 
ated before the injections, after the sixth 30-/~g injection, and after 
1, 6, and 12 mo of study. Induration at the site of lymphokine 
administration was recorded 24 h after each 30-/zg injection. 
Cell Cultures.  Heparinized venous blood was collected for in 
vitro tests, and PBMC were isolated by Ficoll-Hypaque ~harmacia 
Fine Chemicals, Piscataway, NJ) density centrifugation. For mono- 
cyte enrichment, PBMC were rosetted with neuraminidase-treated 
(Vibrio cholera neuraminidase;  Calbiochem-Behring Corp., La JoUa, 
CA) sheep erythrocytes (Calico Biologicals, Inc., Reamstown, PA) 
(8). A total of 10  6 nonrosetted cells (E- population) were cultured 
in 24-well plates (Coming Glass Works, Coming, NY) in 1 ml 
RPMI 1640 (Gibco Laboratories, Grand Island, NY), supplemented 
with 10% pooled AB * serum,  100 U/ml penicillin, 100/~g/ml 
streptomycin, and 2 mM t-glutamine (complete medium). Nonad- 
herent cells were washed away and the adherent ceils were stimu- 
lated with TNF-o~-inducing agonists for 18-20 h, when supema- 
rants were harvested and kept frozen until use (-20~  Blood 
was also used for total leukocyte and differential leukocyte counts. 
Culture Stimulation.  LPS of Salmonella  minnesota R595  (List 
Biological Laboratories,  Campbdl, CA) was diluted in PBS, pH 
7.4, and used at 1/zg/ral; Bacillus Calmette-Guerin (BCG) was 
obtained from Ataulfo de Paiva Foundation (Rio de Jandro, Brazil), 
heat killed, and used at 10 #g/m1. Armadillo-derived M./eprae (ML) 
antigen was provided by Dr. R. J. W. Rees (IMMLEP Bank, The 
National Institute of Medical Research, Mill Hill, England). Cell 
wall protein of ML (CWP-ML), lipoarabinomannan of  ML (LAM- 
ML), and deacylated phenolic glycolipid I of ML (dPGL-I) (pro- 
duced through the National Institute of Allergy and Infectious 
Disease)  were provided by Dr. Patrick Brennan (Department of 
Microbiology, Colorado State University, Fort Collins, CO). Un- 
less otherwise stated, all products were used at 10 #g/ml. Purified 
protein derivative of tuberculin (PPD; Statens Seruminstitut,  Copen- 
hagen, Denmark) was used at 10/~g/ml. Muramyl dipeptide (MDP; 
Sigma Chemical Co., St. Louis, MO) was used at 5 #g/ml. The 
concentration of contaminating endotoxin in stock solutions and 
antigens was estimated by the Limulus amebocyte lysate assay (LAL; 
Whittaker M. A. Bioproducts, Walkersville,  MD). All final cul- 
tures contained <3 pg/ml LPS, suggesting that the TNF-c~ levels 
were induced by the ML products themselves  and not by con- 
taminating LPS (9). 
Thalidomide Preparation.  Thalidomide (the racemic mixture: 
D  [ + ] and L [- ] forms; lot no. JB-I-114) was donated by Andrulis 
Research Corporation (Beltsville, MD) and by Gmnenthal GMBH 
(Stolberg, Germany) (lot no. 1055/8). The compound was dissolved 
in DMSO (Sigma Chemical Co.) at 10 mg/ml, and further dilu- 
tions were made in sterile RPMI, pH 4.0. The compound from 
both companies gave similar results.  The effect of thalidomide on 
in vitro TNF-o~ release is expressed as the mean percent of inhibi- 
tion  _+  SEM (10). 
TNFzr ELISA.  TNF-c~ concentration in serum samples (col- 
lected before and at 4 and 24 h after rlFN-3' injections) and in cell 
culture supematants was determined using a TNF-o~-specific  ELISA 
(Endogen Inc., Boston, MA) as recommended by the manufacturer 
(10). TNF-~x levels are expressed  as nanograms per m~ter  of 
protein. 
Lymphocyte Transformation Test (LTT).  PBMC (2  x  10  s cells) 
were cultured in 96-well  plates  in 200/~1  of complete medium. 
Mycobacterial antigens (ML, 25/zg/ml; BCG, 20/~g/ml, or PPD, 
10/~g/ml) or the mitogen PHA (1%; Gibco Laboratories) were 
added to the cultures, and the assay was performed as described 
(11). Results (cpm) are expressed as Acpm (cpm obtained in stimu- 
lated cultures minus cpm obtained in control cultures). 
Chemiluminescence Assa2/.  PBMC (106 cells) were cultured on 
glass coverslips in 24-well phtes for 2-20 h and washed three times 
with warm RPMI. Coverslips with the adherent cells were then 
transferred to scintillation vials containing 1 ml RPMI with 5% 
FCS. Luminol (5  x  10 -s M; Sigma Chemical Co.) and PMA (0.5 
/~g/ml) (Sigma Chemical Co.) were added to the vials in the dark, 
and respiratory burst activity of monocytes was measured on a/~ 
scintillation counter. Control cells received only luminol. Results 
are expressed as Acpm (cpm obtained from cells stimulated with 
PMA minus cpm obtained in control cells). 
HLA Class II Extrression.  Cytospins were prepared by centrifu- 
gation of 10  s PBMC onto glass slides for 3 min at 800 rpm. After 
air drying, cells were fixed in 3% paraformaldehyde, 75 mM lysine, 
and 10 mM sodium-m-periodate in PBS (PIP) for 10 rain and rinsed 
in PBS. The slides were stored desiccated at -20~  until use. Im- 
munocytochemical staining was performed as described (2) using 
a mouse mAb, 9.3F10 (anti-MHC class II antigen), produced in 
this laboratory (12). 
I~I. Estimation.  Slit smears taken from six sites, including a le- 
sion in each patient, were obtained for whole-body B.I. evaluation 
at the time of diagnosis.  Patients were given MDT for 3-8 mo 
(mean, 3.9 mo) before entering into the study, at which time a 
new B.I. evaluation  was carried out. In addition to the six sites, 
a sample was taken from the back of the patients before rIFN-'y 
injection (seventh site). Patients were retested at the same sites at 
intervals thereafter. In addition, 89 LL/BL patients were evaluated 
for their rate of reduction in B.I. during 18 mo of Mur  alone. 
HistologicalAnalysis.  Biopsies (6-mm punch) of matched, distal 
lepromatous lesions not injected with rlFN~ and not in areas within 
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during,  the rlFN-? injections. In addition, biopsies were taken of 
ENL lesions that developed in response to rlFN-3' treatment.  A 
part of each biopsy was fixed in 10% neutral  buffered formalin 
overnight,  embedded in paraffin, sectioned, and stained with he- 
matoxylin  and eosin for histological diagnosis. 
lramunohistology.  A part of each biopsy specimen was fixed in 
PLP for 3 h, as described (2). This fixative preserves structural de- 
tails without inhibiting  the binding of mAbs to their antigen. Bi- 
opsies were washed in PBS containing sucrose (10%) and digitonin 
(5  x  10 -s M), and then serially suspended in graded solutions of 
sucrose (15-25%).  The tissue was stored at 4~  in PBS with su- 
crose/glycerol (25% and 5%, respectively), embedded in OCT com- 
pound, and frozen at  -20~  Biopsies were sectioned and stained 
as described (13). 
mAbs.  Mouse mAbs were used for the identification of specific 
cell types in frozen tissue sections and on cytospins. Leu-1, Leu-2a, 
and Leu-3a (CD5, CD4, and CD8 anti-T cells) and Leu-M5 (CD11c 
anti-monocyte/macrophage)  (13)were obtained from Becton Dick- 
inson  & Co. (Mountain  View, CA).  Antibody 9.3F10 was pro- 
duced in this laboratory  (12). 
Results 
Clinical Responses to rlFN-9, 
The dose, schedule of administration,  and clinical status 
of the patients receiving rIFN-3' are shown in Table 1. All 
patients received 30/~g i.d. daily for three doses, and a respite 
period of 3 d was followed by another  three injections for 
a total of 180/zg rIFN-'y.  Thereafter,  six patients  (nos.  1, 
2, 6, 7, 8, and 9) received 100 #g i.d.  every 1 mo for 10 mo, 
and four patients (nos.  3, 4, 5, and 10) 100/zg i.d.  every 2 
wk for 5 too. 
The local response to intradermal rlFN-3/of erythemaand 
induration varied widely from patient to patient as noted pre- 
viously (1-3) (Table 1). Reinjectiom into the same site resulted 
in smaller reactions. Almost all patients exhibited mild sys- 
temic symptoms. These included malaise and fatigue (10/10), 
low grade fever enhancement (1~  (5/10), headache and my- 
algia  (3/10),  nausea,  and weight loss (1/10). 
Biopsies of distal skin sites taken I  mo after initiation  of 
rlFN-? injections revealed greater numbers of CD3 + T cells 
in the dermis as compared with preinjection biopsies (not 
shown). However of the 10 patients biopsied, only 4 had ex- 
tensive CD3 + cell counts. In addition, keratinocytes did not 
express HLA class II antigens on their surface in 8 of 10 biopsies 
of the patients  studied. 
The Induction of ENL and Its Therat,  / 
6 of the 10 patients developed ENL during the course of 
their rIFN-? treatment,  as outlined in Table 2. In the early 
phase of low dose intradermal  injections, these were charac- 
terized by single,  painful,  subcutaneous nodules that  were 
transitory in nature and subsided within  8 d.  All of these 
patients developed disseminated,  multiple, painful subcuta- 
neous nodules during the high-dose, bolus injections. There 
was  a  correlation  between areas  of induration  (I>15 mm) 
(Table 1) occurring with intradermal injections and the sub- 
sequent development of ENL (5/6 patients). The typical mi- 
croscopic appearance of biopsied nodules is illustrated in Fig. 
1. These were characterized by dense cellular infiltrates ex- 
tending  from  the lower dermis  into  the subcutaneous fat, 
comprised predominantly of mononuclear cells and granulo- 
cytes. The mononuclear cells (evaluated by immunohistological 
staining)  were  largely  CD3 +  T  ceils  (many  CD4 +)  and 
monocytes,  whereas  the  granulocytes  (evaluated by H&E 
Table  1.  Clinical Status and Response of LL/BL Patients before and after Intradermal rlFN-?  Injection 
Local induration 
B.I.  Duration  of  B.I.  B.I. 
Patient  Diagnosis  MDT"  (Pre)  treatment  Day 3  Day 6  (first month)  (sixth  month) 
mO  mo  mm 
1  BL  4  4.0  12'  16  7  1.6  1.0 
2  LL  4  3.3  12  15  19  3.0  2.1 
3  LL  3  2.5  6s  35  27  2.1  1.3 
4  BL  3  2.3  6  4  8  0.5  1.3 
5  LL  3  2.6  6  32  17  1.6  2.6 
6  BL  3  4.0  12  0  0  2.8  0.3 
7  LL  3  2.9  12  35  25  3.3  2.6 
8  LLs  8  0.5  12  5  0  2.1  2.0 
9  LLs  5  1.5  12  6  7  2.1  1.1 
10  LL  3  1.3  6  18  14  2.0  ND 
* See Materials and Methods. 
* Six injections of 30/~g and one monthly injection of 100/zg each for a total of 10 doses. 
$ Six injections of 30/zg and one injection every 2 wk of 100 #g each for a total of 10 doses. 
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rlFN-3, dose schedule 
30/zg (six doses)  100/zg (10 doses) 
Patient  Time of appearance  Clinical status  Time of appearance  Clinical status 
2  None  None  14 d  after sixth dose  Multiple 
painful nodules 
3  1 d after fifth dose  One painful nodule"  3 d after second dose  Systemic ENL 
5  13 d after sixth dose  One painful nodule  14 d after second dose  Multiple 
painful nodules 
7  1 d after second dose  Two painful nodules  6 d after first dose  Systemic ENL 
8  None  None  1 d after fourth dose  Multiple 
painful nodules 
10  1 d after second dose  Three painful nodules  14 d after third dose  Multiple 
painful nodules 
Course of intradermal rlFN-'y injections included three 30-/~g doses daily, a 3-d respite, and another three 30-/zg injections daily. This was followed 
in 30 d by a 100-/zg dose every 2 wk for  5 too, or every 1 mo for  10 too. 
* Painful nodules in subcutaneous  tissue, 
staining of histological sections) included mostly neutrophils 
and a few eosinophils. Therefore,  these nodules resembled 
the ENL lesions that occur spontaneously in patients receiving 
Mrrr (14). 
Two of the patients developed severe systemic symptoms 
including multiple subcutaneous nodules, fever,  malaise, poly- 
neuritis, arthritis, and weight loss, and required therapy with 
thalidomide.  This symptom complex was also similar to the 
reactional states occurring during chemotherapy. These two 
patients responded promptly to an initial dose of 300 mg/d 
of thalidomide, which was then reduced weekly by 100 mg 
for a total course of 21 d. Within 48 h, fever, malaise, and 
the arthritic and neuritic pain were absent. The tenderness 
of subcutaneous nodules responded just as promptly, and by 
10-15 d the nodules themselves were gone. One of these pa- 
tients (Table 2, no. 3) was treated for 1 wk with thalidomide 
together with all subsequent rlFN-3' injections and did not 
develop further episodes of  ENL. The other patient continued 
to express symptoms of systemic ENL after the next three 
rlFN-y injections. Injections of rlFN-3' were discontinued 
after 4 mo (Table 2,  no. 7). 
The Influence of rlFN-  7  Injections on the B.I. 
Patients receiving MDT demonstrated a gradual reduction 
in the number of acid-fast baciUi in their tissues. The effect 
of chemotherapy alone on the total-body B.I. of 89 LL/BL 
patients was evaluated  over a 12-mo period of therapy. A mean 
_  SEM of 0.6  _+  0.12 log reduction in B.I. was observed 
using slit smear specimens obtained from six sites. The B.I. 
of all 10 patients  receiving rlFN-3,  is shown in Table 1. A 
mean _+ SEM log B.I. reduction during 1 and 6 mo of IFN-3' 
injections was 0.4  +_  0.2 and 0.9  -+  0.3, respectively. The 
values indicated a possible accelerated reduction in systemic 
B.I. in 6 of 10 patients  during the first month of therapy, 
which continued at a slower rate for up to 6 too. 
The Influence of rlFN.  7  on the Function of Circulating 
Cells of Injected LL and BL Patients 
Leukocyte Numbers and MHC Class II Antigen Expression. 
Total leukocyte counts performed on patient bloods collected 
before and 1 h after the sixth 30-#g IFN-3, as wen as 1 h 
after the first 100-#g injection, showed no significant changes 
(mean +_  SEM of white blood ceUs per mm  3 of 7,575  +_ 
890 for pre-IFN-3' bloods and 8,785 _  1,560 for post-IFN-3, 
bloods).  Differential counts for the percent of T  cells and 
monocytes also showed no significant changes (mean percent 
of PBMC for monocytes: pre-IFN-% 4.8%; and post-IFN-% 
5.8%). However, some (25%) patients in ENL had enhanced 
total leukocyte counts (mean, 10,450 _+ 3,088), which were 
accounted for by enhanced numbers of granulocytes, mostly 
PMN leukocytes (ENL,  6,685  +  2,847 vs. LL/BL, 3,949 
_+  627 per mm  3 blood). Immunostaining of PBMC showed 
that the percent of PBMC-expressing MHC class II antigens 
was  not significantly affected after lymphokine injections 
(mean  +_  SEM: 8.7  _  1.3%  positive ceils before vs.  12.5 
_+  2.0 after six 30-#g doses). PBMC isolated from patient 
bloods  contained  a maximum of 5-8%  PMN leukocytes. 
Monocyte Chemiluminescence.  The luminol assay  was used 
as an index of the respiratory burst of monocytes obtained 
from patients before and 4 h after an injection of 30 #g of 
rlFN-3, (Table 3). Both the spontaneous and PMA-stimulated 
activity were increased  after rIFN~ administration, as reported 
previously (1). In addition, monocytes obtained from patients 
who had developed ENL exhibited higher activity in the Lu- 
minol assay  (threefold higher than LL/BL patients). Thalido- 
1732  rIFN-3~  Induction of Erythema  Nodosum Leprosum in Lepromatous Leprosy Figure I.  Light micrographs demonstrating the cellular infiltration in lepromatous and in rlFN-?-induced ENL lesions.  H&E stained  section of 
LL pre-IFN-~ lesion (A) with mostly foam macrophages,  and post-IFN-~/ENL lesion (B and C) with an increase in cellularity  mostly PMN leukocytes 
in B and lymphoid cells in C. Immunohistologic staining for CD3 + T cells (D) and CD4 + T cells (E) of serial sections of ENL lesion (same biopsy 
as B, patient no.  3) and CD3 §  T  cells (F) of another ENL lesion (same as C, patient no.  7).  x 300. 
mide (10-20/~g/ml) added to the cultures  during the assay 
did not affect the activity measured. 
Mitogenic Response of  PBMC.  The thymidine incorpora- 
tion of  PBMC obtained before and after the sixth intradermal 
dose of rlFN-qr  was examined.  No difference was noted in 
the proliferative response to either mitogens (mean cpm  _+ 
SEM: 72,713  +  9,006 vs. 80,917  _  14,456) or the NIL an- 
tigen (mean  cpm  _+  SEM: 927  _+  408 vs.  1,682  +  666). 
Therefore, there was no evidence that rlFN-3' had appreciably 
modified  the T  cell anergy of lepromatous leprosy patients 
to the antigens  of ML. 
Synthesis of TNF~ by Pen'pheral  Blood  Monocytes.  The rel- 
ative efficacy of mycobacterial antigens  for the induction of 
TNF-oe secretion in the absence of IFN-3, was of interest. 
ML and CWP-ML antigens from ML as well as MDP, BCG, 
and PPD gave similar elevations that were "~100-fold above 
unstimulated cultures (Table 4). In contrast, dPGL-I ML failed 
to enhance secretion.  It appears that there may be common 
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the Respiratory Burst Activity of Monocytes  from Lepromatous 
Leprosy Patients 
Luminol assay* 
Leprosy patients  (no. of patients) 
Pre-rlFN-3, injections 
Post-rlFN-3, injections* 
ENL 
1.4 •  0.7 (s) 
3.4  •  1.2 (5) 
4.0  •  1.3 (6) 
* Results are expressed as cpm  x  10-3  •  SEM for each group of pa- 
tients tested. 
t Cells were obtained 4 h after one 30-/~g rlFN-3, injection. 
components of mycobacteria, e.g., MDP, but not the specific 
ML molecule PGbI, which stimulates secretion of TNF-c~ 
from monocytes of lepromatous patients, even in the pres- 
ence of sdective ML T  call anergy. 
Monocyte-em'iched  cultures were examined in LL/BL pa- 
tients for their capacity to produce TNF-ol before and 4 h 
after the injection of a 30-/~g dose of rlFN-%  Monocyte- 
enriched ceils explanted in vitro were exposed to a number 
of antigenic agonists. In the absence of exposure to agonists 
in vitro, and 4 h after the intradermal injection of rIFN-3,, 
only low TNF-c~ concentrations were released (0.06  _+ 0.01 
and 0.08  +  0.02 ng/ml of TNF-c~, respectively). The addi- 
tion of the agonists ML, BCG, and LPS to the monocytes 
in vitro induced levds of secretion of TNF-o~ similar to those 
observed in Table 4 and Fig. 2.  Of interest, however', was 
the higher secretion obtained from monocytes after a single 
intradermal injection of 30/~g rIFN-3, (4 h post-IFN-~/). For 
the ML antigen, this was 2.5-fold higher than uninjected 
BL/LL patients, 4.0-fold higher for BCG, and 5.1-fold higher 
for LPS (mean results for three patients tested). This enhanced 
TNF-ol release had disappeared by 24 h after rIFN-3, adminis- 
tration. It appears that the lymphokine primes monocytes 
Table  4.  Induction of Monocyte TNF-cr Production by 
ML Components 
Agonist  TNF-c~ 
ng/ml 
Control  0.04  +_  0.01" 
ML  5.5  •  0.7 
CWP ML  4.5  +  0.4 
LAM ML  2.0  •  0.4 
dPGL-I ML  0.04  _+  0.01 
MDP  4.7  •  0.8 
TNF-(x release from lepromatous leprosy patient monocytes induced by 
optimal concentrations of ML and other mycobacterial products. 
* Values represent  the mean +_ SEM of 12 different experiments. 
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Figure 2.  Levels  of TNF-o~ released in vitro from monocyte-enriched 
cultures from lepromatous patients. Cells were stimulated with LPS (1 
#g/ml) (A) or BCG (10 #g/ml) (/3) for 20 h. Cells from normal individ- 
uals (N, n  =  8), lepromatous patients without ENL (LL/BL,  n  =  12), 
untreated ENL patients (ENL, n  =  7), and thalidomide-treated (300 #g 
1 d for 1 wk) ENL patients (ENL  +  Thal, n =  6) were tested. Results 
represent means  •  SEM. 
in vivo for transient enhanced antigen-induced TNF-ol secre- 
tion. No TNF-o~ was observed in the serum of patients 4 h 
or 24 h after rlFN-'), administration. 
TNF~c~ Production during ENL and Its Suppression 
by Thalidomide Therapy 
Patients developing generalized  ENL were evaluated for 
the levels of TNF-c~ in the plasma, in PBMC and isolated 
monocytes. Of 14 patients studied, nine had appredable levels 
of plasma TNF-o~ (mean of 2,201  _+  1,178 pg/ml) and the 
other five had no detectable cytokine. 46 patients with LL/BL 
leprosy (not in ENL), 24% had TNF-ot levels in their plasma 
(1,339 _+ 550 pg/ml). TNF-o~ was not detected in the plasma 
of normal controls. Monocyte-enriched cultures obtained from 
aU patients in ENL exhibited elevated levels after exposure 
to a variety of agonists (Fig.  2). The release of TNF-ol in 
response to LPS and BCG from monocyte-enriched  cultures 
of patients in ENL was approximately twofold above that 
seen with uncomplicated LL/BL patients and three- to six- 
fold above normal controls. Similar results were obtained with 
other agonists (not shown). 
Patients with ENL who received thalidomide therapy were 
also examined for the production of TNF-o~ by their mono- 
cytes. As seen in Fig. 2, oral doses of 300 mg/d thalidomide 
resulted in a 50-80% reduction in the ability of monocyte- 
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Patient Monocytes 
TNF-r  release (percent of control) 
ML  MDP  LPS 
IFN-'y  (10/zg/ml)  (5 /zg/ml)  (1 /zg/ml) 
None  100"  100"  100* 
1 U/ml  205  •  32  349 •  93  491  •  188 
10 U/ml  291  _+ 86  549 _+ 95  684 •  225 
100 U/m1  315  _+ 23  628 _+ 99  748 •  236 
Results are the mean  _+  SEM of three different experiments. 
* For range of TNF-c~ release see Table 4. 
) For range of TNF-oe release see Fig. 2. 
enriched cultures to secrete TNF-ot after stimulation with 
LPS and BCG. 
The Influence of rlFN-~/ and Thalidomide When Added 
to Patient's Monocytes In  Vitro 
The previous information suggested that the administra- 
tion of rlFN-3, to patients resulted in a high incidence of 
ENL and enhanced the production of TNF-cr by circulating 
monocytes. Both the inflammatory components of ENL and 
the secretion of monocyte-derived TNF-cr could be inhibited 
by the in vivo administration of thalidomide. In this secre- 
tion we evaluate the effects of IFN-3' and thalidomide when 
added in vitro. 
Monocytes from LL/BL patients were incubated in the 
presence or absence of rlFN-3, for 2-24 h and then assayed 
with and without agonists. Table 5 shows the effects of three 
concentrations of rlFN-3' on TNF-c~ secretion.  Maximum 
release occurred with 100 U/ml of rlFN-3, incubated with 
the cells and agonists for 20 h. Elevated secretion of TNF-c~ 
after rlFN-3, addition failed to occur in the absence of an 
agonist (not shown). In addition, the exposure of monocytes 
to rlFN-'y for as short a period as 2 h was sufficient to prime 
the cells for maximum agonist-induced secretion (not shown). 
The in vitro addition of thalidomide (10/~g/ml) to LL/BL 
patient's monocytes primed and not primed with rlFN-3, in- 
hibited agonist-induced TNF-c~ production to the same ex- 
tent (not shown). The mean percent inhibition +  SEM for 
three different mycobacterial agonists tested is as follows: ML, 
66  _+ 4%; CWP-ML, 60 _+ 16%; MDP, 60 _+ 9%. It there- 
fore appeared that the effects of rlFN-3~ and thalidomide on 
TNF-ot production as exhibited in LL/BL patients in vivo 
could be mimicked by their addition to isolated monocytes 
in vitro. 
Discussion 
After multiple low-dose intradermal rlFN-3, injections ad- 
ministered over a 6- or 12-mo period, ENL was induced in 
a much higher number of patients (60% in 6-7 too) than 
would have been expected during regular MDT in this pa- 
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tient population (15% in 12 too). The severity of the ENL 
symptoms  was dependent on the dose of rIFN-'), administered. 
After the 30-#g-dose injections, only single subcutaneous 
painful nodules were induced, while 100-#g doses induced 
multiple nodules as well as other systemic effects. In most 
patients ENL was easily controlled. The short half-life and 
prompt clearance of the cytokine from the circulation prob- 
ably accounted for the fact that the nodules cleared sponta- 
neously without thalidomide therapy. 
In addition to the IFN-3,-induced ENL, the whole-body 
B.I.  of all 10 patients treated with IFN-q/was reduced by 
a mean log of 0.4 _+ 0.2 and 0.9 _+ 0.3 during the first month 
and 6 mo of treatment, respectively. In comparison, MDT 
alone gave a 0.6  _+ 0.12 log reduction in whole body B.I. 
load during 12 too. The reduction in the systemic ML load 
occurred in the absence of enhanced T cell responsiveness to 
mycobacterial antigens, and thus patient anergy to the bacilli 
remained unaffected.  The mechanism underlying the B.I. 
reduction can be explained by our recent observations.  We 
have previously shown that the local administration of rIFN-3, 
into lepromatous lesions induces accumulation of T cells and 
monocytes, destruction of parasitized macrophages, and a local 
reduction of ML at the site of cytokine injection (1-3). Mul- 
tiple intramuscular (6) as well as intradermal injections of 
the cytokine have given a generalized hypercellularity in the 
skin with a selective enrichment in T  cells and monocytes 
in the lesions. We bdieve that the accumulation of lymphoid 
cells in the dermis led to selective killing of parasitized mac- 
rophages and release of the bacilli into the extracellular space, 
as observed by dectron microscopy (2, 3).  Destruction of 
the host cells could be mediated by a population of cytotoxic 
T  cells and/or NK cells recruited to the site and activated 
locally. Rephagocytosis of the extracellular ML by oxidatively 
competent monocytes (15), activated by IFN-3, locally, might 
lead to killing of the bacilli and their dearance (16). 
These effects of rIFN-3, administration were accompanied 
by monocyte activation for enhanced oxygen radical forma- 
tion as well as an increased release of TNF-ot relative to the 
precytokine levels. Thalidomide therapy,  which rapidly re- 
duced systemic toxicity and the painful subcutaneous nodules 
of ENL, also inhibited the high levels of TNF-ot produced 
by monocytes during ENL. The enhanced secretion of TNF-ot 
could be reproduced by in vitro treatment of monocytes with 
rIFN-3' and was readily reversed in vitro with thalidomide. 
A scenario that could explain these results involves rIFN-3, 
priming of the patient's monocytes for enhanced TNF-tx re- 
lease  (17-19).  Primed monocytes were then triggered by 
mycobacterial  agonists found in high concentrations in the 
circulation as a result of enhanced bacterial killing. Thus, ab- 
normally high levels of TNF-ot, and possibly other cytokines, 
would have been released into the circulation bringing about 
the clinical symptoms and toxicities of ENL. Thalidomide 
would be so effective at controlling ENL because it reduces 
TNF-oe levels released by monocytes. 
It is not clear whether a similar scenario is involved in the 
generation of ENL in patients treated with MDT alone. The 
initiation of therapy would give rise  to bacterial  killing, 
releasing into the circulation ML components capable of trig- gering TNF-cz secretion from monocytes and macrophages 
(20-22).  We have demonstrated that ENL patient's mono- 
cytes rdease higher levds of TN1Lo~ than do cells from normal 
controls or BL/LL patients not in reaction.  The ENL pa- 
tients also have high TNF-c~ plasma levels in the circulation 
(23). Whether IFN-~/is involved in this process is unknown. 
IFN-3,-producing cells were shown to be increased in the le- 
sions of lepromatous patients during ENL (24). The emer- 
gence of T  cells reactive to ML during ENL has also been 
suggested (25,  26), but this response appears transient. 
The ef~cacy of thalidomide in ENL and its inability to 
modify the course of reversal reaction suggest differences in 
the underlying pathophysiology of these two reactional states 
(27-29). Enhanced T  cell responsiveness is a prominent lea- 
ture of the reversal  reaction,  and lesions of skin and nerve 
are characterized by mononuclear infiltration.  In contrast, ENL 
has little or no enhancement of T cell reactivity and exhibits 
mixed cellular infiltrates containing both granulocytes and 
mononudear  cells.  ENL exhibits extensive vasculitis prob- 
ably as a result of the high TNF-c~ levels and the activation 
of the complement cascade. It is the systemic, toxic manifesta- 
tions of this state and others (30, 31) that are so responsive 
to thalidomide. Two possibilities are suggested by these con- 
siderations. The first is that mycobacterial products serve as 
particulate agonists of monocyte cytokine synthesis, including 
TNF-ol,  and the second is that the large number of tissue 
granulocytes make appreciable amounts of TNF-c~ (32-34). 
These points are now being explored in our laboratory. 
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